European Medicines Agency

The European Medicines Agency (EMA) is the regulatory body of the European Union responsible for the scientific evaluation, supervision, and safety monitoring of medicines for human and veterinary use. It assesses whether medicinal products meet the required standards of quality, safety, and efficacy before they can be marketed in the EU. Its opinions lead to centrally authorised marketing authorisations that are valid across all member states, streamlining access to new therapies. The agency also provides scientific advice to developers and oversees the safety of medicines once they are on the market.

Headquartered in Amsterdam, the Netherlands, the EMA operates as a decentralized EU agency, working closely with the national competent authorities of the 27 member states. Through this network, it coordinates assessments, shares information, and ensures consistent application of EU pharmaceutical legislation. The agency’s reach extends to the entire EU population, as its decisions affect the availability of medicines for over 440 million citizens. It also contributes to global health by collaborating with international regulators and the World Health Organization.

The EMA’s distinguishing attribute is its role as the centralised evaluator for medicines in the EU, supported by specialised scientific committees such as the Committee for Medicinal Products for Human Use (CHMP) and the Pharmacovigilance Risk Assessment Committee (PRAC). These committees provide independent expert opinions that shape the agency’s recommendations. During the COVID‑19 pandemic, the EMA led the rapid evaluation and authorisation of several vaccines, including the Pfizer/BioNTech product, demonstrating its capacity to handle high‑volume, urgent assessments. The agency also maintains transparency by publishing meeting minutes and assessment reports, although it suffered a breach in December 2020 when threat actors accessed, altered, and leaked confidential vaccine data to undermine public trust.

Structurally, the EMA is an agency of the European Union, established in 1995, and is accountable to the European Parliament and the Council of the European Union. Its financing comes from a combination of EU subsidies and fees paid by pharmaceutical companies for services such as protocol assistance and marketing authorisation applications. The agency is not owned by any private entity; it functions as a public institution serving the collective interest of EU member states. Its governance includes a Management Board composed of representatives from the Member States, the European Commission, and the European Parliament.